In patients with prostate cancer undergoing hormone therapy, the use of SGLT2 inhibitors was associated with significantly reduced all-cause mortality as well as lower risks of heart failure, HF exacerbations, peripheral artery disease, atrial fibrillation, cardiac arrest, and the need for renal replacement therapy. The gene discussed is SLC5A2; the disease is prostate cancer.